04 July 2022, Mumbai: UPL Ltd. today announced the launch of ‘Kevuka’ in India containing the patented active ingredient Flupyrimin to target the most damaging rice pests brown plant hopper. The launch in India across various major markets is planned in Kharif crop sowing season.
The recent launch was done in Raichur in Karnataka in the presence of 500 trade partners and farmers, with Dr. AG Sreenivas, Prof & Head, Dept of Entomology, UAS Raichur briefing the audience on the paddy pest management’s changing scenario. The audience witnessed how this revolutionary molecule having effective control against both yellow stem borer (YSB) & brown plant hopper (BPH) would lead to increase in farm income.
With the introduction of Kevuka growers can experience assured protection during the most critical growth stages of their rice crop.
Kevuka (Technical: Flupyrimin 2% GR) is a novel insecticide with unique biological properties and long residual control, effective against major rice pests such as Brown Plant Hopper (BPH) and Yellow Stem Borer (YSB). Extensive demonstration trials have shown that Flupyrimin protects rice yields from the damage of YSB & BPH and boosts crop health, further supporting farmers’ economic resilience and productivity. Kevuka is also effective on pest populations resistant to existing insecticides.
Mike Frank, President and COO at UPL, said: “Flupyrimin is a breakthrough technology promising a leap forward in pest management for rice growers. With market access maximised through UPL’s wide- range distribution channels and differentiated branding strategy, the introduction of Kevuka in India marks another fundamental milestone of our collaboration with MMAG under our OpenAg® vision.”
Ashish Dobhal, UPL Region Head for India, said: “India is the world’s second largest producer of rice and the largest exporter of this staple crop. Growers here have been waiting for a one-shot effective solution to protect against different rice pests. Through Kevuka, UPL is delivering unmatched control of YSB and BPH.”
Flupyrimin was discovered through a collaboration between MMAG and the Prof. Kagabu group. It was first registered in Japan in 2019.
